Summit Therapeutics Inc. · NASDAQ:SMMT
Summit Therapeutics — Investor Presentation (February 2023)
9 slides from Summit Therapeutics's investor presentation, February 2023
Slide 1: Committed to Optimizing Human Health
Committed to Optimizing Human Health
Slide 2: Our Mission Overview and Our Leadership
OUR MISSION OVERVIEW To build a viable, long-lasting health care organization that assumes full Summit Therapeutics’ timeline of key events from 2020 through 2022. responsibility for designing, developing, trial enrollment, regulatory approval, and commercializing patient-, physician-, caregiver-, p
Slide 3: Our Strategic Partnership With an Aligned Mission
OUR STRATEGIC PARTNERSHIP WITH AN ALIGNED MISSION Bringing Ivonescimab to Patients in Need Summit Therapeutics, Inc. has announced a definitive agreement of its partnership with Akeso Inc. (HKEX Code: 9926.HK, “Akeso”), to in-license its breakthrough bispecific antibody, ivonescimab. Akeso is a pion
Slide 4: Ivonescimab (SMT112) PD-1/VEGF Bispecific Antibody
IVONESCIMAB (SMT112) PD-1/VEGF BISPECIFIC ANTIBODY Ivonescimab is a novel, potential first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking of VEGF into a single molecule. • Ivonescimab is the most
Slide 5: Ivonescimab Received Breakthrough Therapy Designation Status in China for Three Indications
IVONESCIMAB RECEIVED BREAKTHROUGH THERAPY DESIGNATION STATUS IN CHINA FOR THREE INDICATIONS • Combined with chemotherapy for NSCLC patients who have failed a previous EGFR-TKI • Combined with chemotherapy for NSCLC patients who have failed to respond to a prior PD-(L)1 therapy • Monotherapy as first
Slide 6: Summit Oncology Pipeline
SUMMIT ONCOLOGY PIPELINE ONCOLOGY CANDIDATE DISCOVERY PRECLINICAL PHASE I/II PHASE III REG SUBMISSION APPROVED Ivonescimab (SMT112) NSCLC* First indication NSCLC* Second indication NSCLC* Third indication Summit In-house Discovery Target not disclosed Small molecule Target not disclosed Small molecu
Slide 7: Our Commitment to Lead the Industry Forward
OUR COMMITMENT TO LEAD THE INDUSTRY FORWARD OUR TEAM The Summit team has extraordinary experience, from drug discovery through commercialization. At Summit Therapeutics, we are proud to have talented, passionate people on our team. We pride ourselves on the experience and expertise every individual
Slide 8: Contact
CONTACT info@smmttx.com investors@smmttx.com media@smmttx.com medicalinformation@smmttx.com smmttx .com
Slide 9: Contact
Contact investors@smmttx.com Summit Therapeutics offices are located in Menlo Park, CA; Oxford & Cambridge, UK www.smmttx.com Trademarks, registered or otherwise, are the property of their respective owner(s). © 2023 Summit Therapeutics Inc. 174-020823
Summit Therapeutics — Investor Presentation (February 2023) on 6ix